You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

COVID-19: Get the latest updates or take a self-assessment.

Systemic therapy of denosumab in altering surgical outcomes in patients with giant cell tumour of bone

ID: ES 11-13 Feb 2021
Type of Content: Guidelines & Advice, Evidence Summary
Document Status: Current
Authors:
A. Gupta, L.D., Durocher-Allen, S. Popovic, R. Tozer, X. Yao, and M. Ghert

Guideline Objective:

To provide evidence on the benefits (i.e. effectiveness) and harms of DENO to inform provider/patient decision in patients with GCTB, BFHB, or ABC.

Patient Population:

Skeletally mature adolescents (aged ≥ 12 years) and adults with GCTB, BFHB, or ABC undergoing DENO treatment. This includes patients with resectable disease, unresectable disease, recurrent disease, and primary disease.

Intended Guideline Users:

Medical oncologists, orthopedic oncologists, pathologists, and other clinicians involved in the care of patients with GCTB.

Research Questions:

For patients with GCTB, BFHB, and ABC, what are the benefits and harms in terms of facilitation of surgery, disease recurrence, pain control, disease stability and adverse effects of denosumab use?

pdf download Full Report (PDF) (225.7 KB)